S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SLS · SELLAS Life Sciences Group, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Sellas Life Sciences Group Inc (SLS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$12.15
+0.16
(+1.29%)
● At close: October 21 at 4:00:00 PM EDT
$12.15
+0.01
(+0.08%)
Overnight:
8:25:42 PM EDT
DAY'S RANGE
$12.15
$11.88
$12.33
52-WEEK RANGE
$12.15
$1.39
$15.88
What's happening
- SLS is up 1.29% today, trading at $12.15. — Live quote
- Volume today (170,479) is well below its 3-month average of 7,635,280. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.05 actual vs. $-0.05 estimated (-9.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 1
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SLS
+217.77%
vs S&P 500
+204.99%
1-YEAR RETURN
SLS
+496.02%
vs S&P 500
+481.46%
6-MONTH RETURN
SLS
+143.00%
3-MONTH RETURN
SLS
-7.13%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.05
Est. $-0.05
MISS -9.9%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.04
MISS -23.8%
2026-01-26 (Q4 2025)
$-0.05
Est. $-0.07
BEAT +23.9%
2025-10-26 (Q3 2025)
$-0.06
Est. $-0.07
BEAT +10.0%
Valuation Measures & Ratios
Enterprise Value4$2.19B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)802.56
Price / Book721.08
EV4 / Revenue754.86
EV4 / EBITDA—
Profit Margin-736.21%
Operating Margin-730.69%
Return on Equity (ROE8)-35.91%
Return on Assets (ROA9)-33.34%
Avg Volume (3M)7,635,280
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.84B | $709.6M | $182.2M | $203.7M | $89.7M |
| P/E | -90.32 | -25.70 | -6.93 | -7.55 | -2.99 |
| Price/Book | 20.60 | 6.61 | 3.99 | 7.79 | 3.23 |
| ROE | -22.81% | -25.71% | -57.67% | -103.22% | -107.92% |
| ROA | -21.60% | -24.18% | -51.04% | -83.55% | -85.70% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short55,128,974
Change from Prior Settlement-6.67%
% of Float—
Days to Cover (Short Ratio)9.45
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +496.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -736.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SLS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.6M | -$9.3M | -$7.1M | -$6.9M | -$6.1M | -$7.3M | -$7.6M | -$9.6M |
| Net income | -$9.6M | -$8.4M | -$6.8M | -$6.6M | -$5.8M | -$7.1M | -$7.5M | -$9.6M |
| EPS (diluted) | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.10 | $-0.13 | $-0.21 |
| EPS (basic) | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.10 | $-0.13 | $-0.21 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $145.4M | $114.2M | $78.3M | $51.6M | $32.3M | $35.0M | $19.4M | $26.5M |
| Total liabilities | $7.7M | $6.8M | $7.5M | $5.9M | $6.2M | $7.2M | $10.0M | $10.6M |
| Stockholders' equity | $137.7M | $107.4M | $70.9M | $45.6M | $26.1M | $27.8M | $9.5M | $15.9M |
| Total current assets | $142.5M | $111.2M | $75.2M | $49.1M | $29.4M | $32.0M | $16.3M | $24.0M |
| Total current liabilities | $7.6M | $6.5M | $7.0M | $5.9M | $6.0M | $6.9M | $9.5M | $10.6M |
| Cash & equivalents | $138.3M | $107.1M | $71.8M | $44.3M | $25.3M | $28.4M | $13.9M | $21.0M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M |
| Accounts payable | $3.1M | $3.6M | $2.9M | $2.3M | $3.3M | $3.8M | $3.5M | $4.5M |
| Accrued liabilities | $3.9M | $2.3M | $3.5M | $3.0M | $2.1M | $2.6M | $5.5M | $5.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K |
| Retained earnings | -$293.0M | -$283.4M | -$275.0M | -$267.3M | -$260.5M | -$253.9M | -$248.1M | -$241.4M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.6M | -$8.8M | -$4.9M | -$7.1M | -$7.3M | -$9.1M | -$7.2M | -$7.8M |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | $38.8M | $44.1M | $32.4M | $26.1M | $4.2M | $23.6M | $8.0K | $19.7M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $1.0M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$547.0K | $685.0K | $660.0K | -$1.0M | -$441.0K | $277.0K | -$1.1M | -$1.8M |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $527.0K | — | — | — | $64.0K | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.0M | $7.6M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M |
| EPS (diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| EPS (basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| Operating margin | — | — | — | -$4.2K | -$333 |
| Net margin | — | — | — | -$4.1K | -$272 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M |
| Stockholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M |
| Total current assets | $75.2M | $16.3M | $3.2M | $17.8M | $23.0M |
| Total current liabilities | $7.0M | $9.5M | $13.7M | $15.5M | $5.0M |
| Cash & equivalents | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M |
| Accounts receivable | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — |
| Goodwill | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M |
| Accounts payable | $2.9M | $3.5M | $5.6M | $3.4M | $2.1M |
| Accrued liabilities | $3.5M | $5.5M | $7.7M | $6.3M | $2.6M |
| Deferred revenue (current) | — | — | — | — | $0 |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K |
| Retained earnings | -$275.0M | -$248.1M | -$217.2M | -$179.9M | -$138.6M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M |
| Investing cash flow | — | $0 | -$5.5M | -$4.5M | $0 |
| Financing cash flow | $86.3M | $46.8M | $22.3M | $24.1M | $12.1M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $2.0M | $1.6M | $2.1M | $1.7M | $1.0M |
| Deferred income taxes | — | — | — | $0 | -$239.0K |
| Change in accounts receivable | — | — | — | — | — |
| Change in inventory | — | — | — | — | — |
| Change in accounts payable | -$535.0K | -$2.1M | $2.3M | $1.2M | -$2.5M |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $527.0K | $64.0K | $31.0K | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SLS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-12-04 to 2026-06-16
Recent transactions
- Most recent: Stergiou Angelos M. (President and CEO) — Grant / award of 1,065,000 shares on 2026-06-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Stergiou Angelos M. | President and CEO | Grant / award | 2026-06-16 | 1,065,000 |
| Varian John | Director | Grant / award | 2026-01-07 | 50,000 |
| VAN NOSTRAND ROBERT L | Director | Grant / award | 2026-01-07 | 50,000 |
| SCHEINBERG DAVID A | Director | Grant / award | 2026-01-07 | 50,000 |
| CICIC DRAGAN | SVP, Chief Development Officer | Grant / award | 2026-01-07 | 300,000 |
| Burns John Thomas | CFO | Grant / award | 2026-01-07 | 300,000 |
| Kalin Katherine Bach | Director | Grant / award | 2026-01-07 | 50,000 |
| Wasman Jane | Director | Grant / award | 2026-01-07 | 50,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. | President and CEO | Grant / award | 1,065,000 | $0.00 |
| 2026-01-07 | Varian John | Director | Grant / award | 50,000 | $0.00 |
| 2026-01-07 | VAN NOSTRAND ROBERT L | Director | Grant / award | 50,000 | $0.00 |
| 2026-01-07 | SCHEINBERG DAVID A | Director | Grant / award | 50,000 | $0.00 |
| 2026-01-07 | CICIC DRAGAN | SVP, Chief Development Officer | Grant / award | 300,000 | $0.00 |
| 2026-01-07 | Burns John Thomas | CFO | Grant / award | 300,000 | $0.00 |
| 2026-01-07 | Kalin Katherine Bach | Director | Grant / award | 50,000 | $0.00 |
| 2026-01-07 | Wasman Jane | Director | Grant / award | 50,000 | $0.00 |
| 2025-12-03 | CICIC DRAGAN | SVP, Chief Development Officer | Other acquisition/disposition | 63,800 | $1.50 |
| 2025-12-03 | Burns John Thomas | CFO | Other acquisition/disposition | 58,592 | $1.50 |
| 2025-12-03 | Stergiou Angelos M. | President and CEO | Other acquisition/disposition | 187,066 | $1.50 |
| 2025-11-19 | Kalin Katherine Bach | Director | Open market purchase | 63,400 | $1.59 |
| 2025-06-12 | VAN NOSTRAND ROBERT L | Director | Open market purchase | 10,000 | $1.48 |
| 2025-05-30 | Wasman Jane | Director | Open market purchase | 20,000 | $1.69 |
| 2025-05-22 | Kalin Katherine Bach | Director | Open market purchase | 20,000 | $1.80 |
| 2025-01-10 | Burns John Thomas | CFO | Grant / award | 113,000 | $0.00 |
| 2025-01-10 | Burns John Thomas | CFO | Grant / award | 81,300 | $0.00 |
| 2025-01-10 | Stergiou Angelos M. | President and CEO | Grant / award | 257,000 | $0.00 |
| 2025-01-10 | Stergiou Angelos M. | President and CEO | Grant / award | 243,900 | $0.00 |
| 2025-01-10 | SCHEINBERG DAVID A | Director | Grant / award | 12,500 | $0.00 |
| 2025-01-10 | Wasman Jane | Director | Grant / award | 12,500 | $0.00 |
| 2025-01-10 | VAN NOSTRAND ROBERT L | Director | Grant / award | 12,500 | $0.00 |
| 2025-01-10 | Kalin Katherine Bach | Director | Grant / award | 12,500 | $0.00 |
| 2025-01-10 | Varian John | Director | Grant / award | 12,500 | $0.00 |
| 2025-01-10 | CICIC DRAGAN | SVP, Chief Development Officer | Grant / award | 113,000 | $0.00 |
| 2025-01-10 | CICIC DRAGAN | SVP, Chief Development Officer | Grant / award | 81,300 | $0.00 |
| 2024-12-04 | CICIC DRAGAN | SVP, Chief Development Officer | Other acquisition/disposition | 8,256 | $1.13 |
| 2024-12-04 | Stergiou Angelos M. | President and CEO | Other acquisition/disposition | 28,289 | $1.13 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:41 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-24 | View on SEC.gov → |
| 2026-06-25 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-16 | View on SEC.gov → |
| 2026-06-18 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-02 | 8-K | 2026-06-02 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-03-19 | 8-K | 2026-03-19 | View on SEC.gov → |
| 2026-03-19 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-11 | 8-K | 2026-03-11 | View on SEC.gov → |
Recent news
Headlines about SLS (SELLAS Life Sciences Group, Inc.). Links open the publisher — we don’t host full articles.
-
Nasdaq, S&P 500 Futures Mixed As Oil Surge, Trump Tariffs Cloud Market Outlook: Why INTC, TSLA, SPCX, ORCL, SLS Are In Focus
Stocktwits · 2026-10-21 -
Nasdaq, S&P 500 Futures Climb As Wall Street Awaits AMD, SpaceX Earnings After Palantir Rally: Why SNAP, AMZN, SNDK, LCID, SLS, ASTS Are In Focus
Stocktwits · 2026-10-21 -
SLS Stock Climbs As New SLS009 Data Fuels Biotech Momentum
StocksToTrade · 2026-10-20 -
SLS Stock Gains Attention On Bullish SLS009 Pancreatic Data
Timothy Sykes · 2026-10-20 -
SELLAS Life Sciences Group Inc. Stock Grades | SLS
Barron's · 2026-10-20 -
Why Are Nasdaq Futures Falling Premarket? CRWV, NBIS, TSLA, SPCX, MU, ASTS, NFLX, SLS Stocks In Focus
Stocktwits · 2026-10-20 -
SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years
Yahoo Finance · 2026-10-20 -
Why SELLAS Life Sciences Group Stock Is Up 5.1% And What's Next
Simply Wall Street · 2026-10-20
No headlines in this category right now — try “All”.